Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

DURECT Corporation (DRRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8956-0.0782 (-8.03%)
At close: 04:00PM EST
0.8956 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement
Sign in to post a message.
  • R
    Richard
    Just an opinion, I’ve been this for over two years now and have watched the SP slowly erode to where it is now, just under a dollar. Even though DRRX has an approved product, you have to wonder what mgmt is doing to bolster the share price so it doesn’t degrade the value of the company any further than it already has. Maybe it’s time for the shareholders to start questioning the capabilities of those in the C-Suite? They’re collecting their salaries yet the shareholders are paying them good money to manage the company with little or no benefit to us shareholders. Is there any good news that the company can share that would give us shareholders any sense of the company is making any progress on the phase 2 studies? With the share price dropping like it is, one has to wonder just how long it will be before the company will have to issue more shares further diluting the share price. How does anyone else feel about how the company is being run?
  • g
    guttums
    My take on DRRX
    1. The stock price will go up at least by another 50 cents with Posimir news.
    2. To me Posmir is a small potato when I think of the big picture.
    3. After the AHFIRM positive data results the stock price will be $5 to $10.
    4. Very very likely the AHFIRM trial ill be a huge success.
    5. The DUR 928(Larsucosterol) has too many great potentials of success ith future trials.
    6. Soon the NASH trial will start.
    7. DRRX is a target for acquisition ?? may be a price of $20 to 30.
    I am hanging in there so that I can retire rich.
    Bullish
  • A
    Anonymous
    Down almost 20% for the month and almost 50% for the year. Will it rebound???
  • A
    Anonymous
    If you need help on whether or not to invest here just look at the 21-year chart. That will tell you all you need to know. Oh, and who is running this sinking ship.
  • A
    Andy
    Why the pop today? Any news?
  • j
    jim b
    the clock is on reverse split
  • A
    Anonymous
    I don’t think longs realize that this needs to go up about 150% just to get back to where it was once Posimir was approved.
  • d
    don't cheat.
    The future for your investment depends on 928 period! This is a yes/no choice. If yes meaning 928 a success buy what you can! If no it’s lost or a tax write off! Easy 10x with yes.
  • j
    j37
    Disappointing Posimir sales but... a good sign that they are getting into more formularies -- an even better sign that there are substantial repeat sales. This means the surgeons are happy with it. The numbers may not be spectacular now but there is great growth potential.

    The development costs are water under the bridge so unless you are a wound licker you don't really care about ROI. The real value in Posimir was the experience they gained that has been carried forward into the subsequent drugs.

    There is huge potential in epigenetic regulation. There is great hope for alcoholic and non-alcoholic hepatitis treatments. Did anyone else notice the part about showing promise against multi-organ dysfunction syndrome? MODS is highly fatal and after it gets rolling there isn't any good treatment.
  • m
    mediagaslightingyou
    "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today preliminary results from the first five patients treated with leronlimab in its Phase 2 trial for NASH (nonalcoholic steatohepatitis) open label. These preliminary findings from five patients treated with leronlimab suggested fatty deposits were lowered on all 5 patients by as much as 45%, as compared to the baseline measurement. In addition, fibrosis was also lowered by as much as 10%, in 4 out of 5 patients as compared to the baseline measurement (one patient exhibited no change in fibrosis).
    The Phase 2 trial for 90 patients is designed to test whether leronlimab may inhibit the devastating liver fibrosis associated with NASH. As previously reported, the Company’s preclinical study demonstrated strong positive data, highlighting the potential of leronlimab in treating nonalcoholic fatty liver disease (NAFLD), a common precursor to NASH. Inhibition of CCR5 has been shown to be effective in reducing fibrosis in animal models of NASH liver fibrosi
  • D
    Dawn
    Will it ever see $1.65 again?
  • J
    James
    I think we might break $1 again
  • J
    James
    Talk about a falling knife
  • W
    William
    up 13% on triple average volume. on a Friday. Pretty good indication there might be some good news coming?
    Bullish
  • A
    Anonymous
    Get ready, new low coming?
  • A
    Anonymous
    Just like all the other conferences, meetings, fireside chats….once they happen share price tanks. What good is a “poster” presentation going to do. Says a lot about the DUR-928 program.
  • m
    mediagaslightingyou
    if posimir was relevant, they would be knocking down the door to get a piece of it... instead, durect will have to practically give it away to get a partner... what a waste of time and money... what is ROI between R&D, and trials??
  • S
    Scheister
    There are some similarities between how Remoxy went through trials and where DUR928 currently stands. Of course, while Remoxy was in the midst of FDA trials the initial development of Posimir was just beginning. However, there is one major difference between the Remoxy and 928. In Remoxy, there was no mystery that the drug WAS EFFECTIVE. FDA had made it clear from the getgo that Durect had to prove that the drug's effectiveness meant pain relief and that it prevented addiction. So, Remoxy had a safety issue.

    The question concerning 928: is it effective? It's not a safety issue. Early results seem to point to 928 being well accepted. Is it EFFECTIVE? That's the question. Although Durect doesn't have full Phase 2 enrollment, the company has to have been collecting effectiveness data since Phase 1. Early results must be positive. Perhaps this pop from $1.20 has something to do with the dog and pony tour they've been on.

    Obviously, Durect has presented at investment panels for years. Recent attendance at these events feels different this time. Phase 2 enrollment has been ongoing. Yes, we've been waiting for a Posimir partner and yes, rights are important. Looking back at all the partnering agreements over the years, I'm hoping Jimbo has learned something.

    Partnering with Pain (now SAVA), King, Pfizer, both good and bad was always from the perspective of rights and royalties.

    Maybe Durect should be looked at from an M&A opportunity? Here is a company that really hasn't been managed to the best of its ability. It now has an FDA-approved application for limited use but could have the potential for approval in a wide array of surgical procedures if someone was big enough to throw some cash at it. Results from 928 have been positive but not truly official in FDA's eyes. Data from trials to date seem to point at safety not being issued. Data on 928's effectiveness has been collected all along the way... maybe worth a risk considering the potential market of 928 as being game-changing. These little fireside chats may be to find a suitor, not just a Posimir partner. Jump into the NASH game mid-Phase 2, and get a pretty good surgical application that has FDA approval, as a bonus.

    It's awfully strange that the dog and pony show coincides with the strong trading since we were trading in the low $1.20's not too long ago. JimBo has set some deadlines he couldn't meet in finding a Posimir partner...maybe he's finally found something.

    Nice pop for a Friday.
  • J
    James
    I am so so happy I own this stock 😊

    ...not

    But in all honesty, when there are no more bulls, that's normally when the tide will turn
  • S
    Scheister
    in the interview One aspect of this that may not be appreciated is that some AH patients at the highest risk of death receive liver transplants if they meet strict eligibility requirements and a liver is available for them. If DUR-928 can reverse the course of that patient’s AH, the donated liver that would have gone to that patient would now be available for another patient waiting on the liver transplant list. So, saving one AH patient’s life may also save the life of the patient who was next in line on the transplant list.
Advertisement
Advertisement